{"url_path":"/sec/aytu/10-q/2026/item-2","section_key":"item-2","section_title":"Item 2 MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS**","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-13","source_url":"https://www.sec.gov/Archives/edgar/data/1385818/0001437749-26-016721-index.html","accession_number":"0001437749-26-016721","cik":"0001385818","ticker":"AYTU","issuer_name":"AYTU BIOPHARMA, INC","edgar_url":"https://www.sec.gov/Archives/edgar/data/1385818/0001437749-26-016721-index.html","primary_entity_key":"0001385818","primary_entity_name":"AYTU BIOPHARMA, INC"},"word_count":5273,"has_tables":true,"body_markdown":"**ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS**\n\n \n\n*This discussion should be read in conjunction with the Company’s 2025 Form 10-K. The following discussion and analysis contain forward-looking statements that involve risks and uncertainties. Actual results could differ materially from those projected in the forward-looking statements. For additional information regarding these risks and uncertainties, please see the risk factors included in the Company’s 2025 Form 10-K, and in Part II, Item 1A of this Form 10-Q.*\n\n \n\n**Objective**\n\n \n\nThe purpose of the Management’s Discussion and Analysis (the “MD&A”) is to present information that management believes is relevant to an assessment and understanding of our results of operations for the three and nine months ended March 31, 2026, our cash flows for the nine months ended March 31, 2026, and our financial condition as of March 31, 2026. The MD&A is provided as a supplement to, and should be read in conjunction with, our unaudited consolidated financial statements and notes thereto.\n\n \n\n**Overview**\n\n \n\nWe are a pharmaceutical company focused on advancing innovative medicines for complex CNS system diseases to improve the quality of life for patients. Our strategy is to become a leading pharmaceutical company that improves the lives of patients. We use a focused approach of in-licensing, acquiring, developing and commercializing novel prescription therapeutics in order to continue building our portfolio of revenue-generating products and leveraging our commercial team’s expertise to build leading brands within large therapeutic markets. In June 2025, we entered into the Commercialization Agreement with Fabre-Kramer to commercialize EXXUA in the United States. Gepirone is a new chemical entity and EXXUA is a novel first-in-class selective serotonin 5HT1a receptor agonist and is approved by the FDA for the treatment of MDD in adults.\n\n \n\nEXXUA has been extensively studied in over 5,000 patients and represents a new class of therapeutics to compete in the over $22 billion United States prescription MDD market. We believe EXXUA can become a very important treatment option for the estimated 21 million Americans affected by MDD. Over 340 million antidepressant prescriptions were written in 2024 in the United States, yet significant unmet needs remain considering the unacceptable side effects associated with current therapeutics. Importantly, we believe that EXXUA is the only antidepressant acting on serotonin receptors that does not carry a label warning about the risk of sexual dysfunction. The mechanism of the antidepressant effect of EXXUA is believed to be related to its modulation of serotonin activity and, specifically, its exclusive and strong binding affinity for 5HT1a receptors, which are key regulators of mood and emotion. EXXUA is not a Selective Serotonin Reuptake Inhibitors (“SSRI”) or a Serotonin-Norepinephrine Reuptake Inhibitors (“SNRI”) and has no reuptake inhibition activity. EXXUA also exhibits no significant adverse effects on weight, blood pressure, heart rate or liver function. We successfully launched EXXUA in the second quarter of fiscal 2026 as the centerpiece of our commercial efforts. It is our expectation that EXXUA has the potential to serve as a major growth catalyst for us.\n\n \n\nIn addition, we will continue to commercialize innovative prescription products that address other CNS conditions, including ADHD. We are focusing our efforts on accelerating the growth of our commercial business and achieving positive operating cash flows. To achieve these goals, we indefinitely suspended active development of our clinical development programs and have wound down and divested unprofitable operations. In the first quarter of fiscal 2025 we completed the previously announced wind down and divestiture of our Consumer Health business and now operate our business as a single operating and reporting segment. The accounting requirements for reporting the Consumer Health business as a discontinued operation were met when the wind down and divestiture was completed on July 31, 2024. Accordingly, our unaudited consolidated financial statements for all periods presented reflect the Consumer Health business as a discontinued operation.\n\n \n\n31\n\n[Table of Contents](#toc)\n\n \n\nOur business from continuing operations is focused on the commercialization of our prescription pharmaceutical products sold primarily through third party wholesalers, distributors and pharmacies and which primarily consists of three product portfolios. The first consists of EXXUA for the treatment of MDD; the second, the ADHD Portfolio, consists of products for the treatment of ADHD; and the third, the Pediatric Portfolio, consists of a line of legacy products. We contract with CMOs for the manufacture and testing of all of our products.\n\n \n\nWe have entered into two international exclusive collaboration, distribution and supply agreements to commercialize certain of our ADHD products. The first agreement is with Medomie, a privately owned pharmaceutical company, which will commercialize the ADHD products in Israel and the Palestinian Authority. The second agreement is with Lupin, a subsidiary of global pharmaceutical company Lupin Limited, which will commercialize the ADHD products in Canada. We will supply the ADHD products to Medomie and Lupin based on forecasts and provide various product commercialization, regulatory and quality assurance resources. Medomie and Lupin are responsible for seeking local regulatory approvals and marketing authorizations for the ADHD products, which is expected to occur over the next 18 to 24 months, however, there can be no guarantee that local regulatory approvals and marketing authorizations will be obtained on the expected timeline.\n\n \n\nIn light of our own business activities and external developments in the biotechnology and biopharmaceutical industries, Aytu management and our Board of Directors regularly reviews our performance, prospects and risks such as the potential impact to our business resulting from our competitive landscape (i.e., entry of generic competitors, payor pressures, new branded entrants, etc.). These reviews have included consideration of potential partnerships, collaborations, and other strategic transactions such as acquisitions or divestitures of programs or technology to enhance stockholder value. Aytu management and our Board expect to continue to evaluate potential strategic transactions and business combinations.\n\n \n\n**Business Environment**\n\n \n\nWe continue to experience inflationary pressures and economic uncertainty caused by global geopolitical factors, trade wars and tariffs, and members of our industry are currently encountering supply chain disruptions related to the sourcing of raw materials, increased costs of materials as result of tariffs, energy, logistics and labor for a number of reasons, including ongoing geopolitical events. It is possible that trade wars and economic or political policies could adversely affect some of our markets and suppliers, economic and financial markets, costs and availability of energy and materials, or cause further supply chain disruptions. Inflationary pressures, increased costs and supply chain disruptions could be significant across the business throughout fiscal 2026 and into fiscal 2027. Understanding these risks, we have not experienced stock outages for our ADHD products since the launch of those products.\n\n \n\nIn October 2024, we received the Notice Letter from Granules, stating that it intends to market a generic version of Adzenys before the expiration of all patents currently listed in the Orange Book. The Notice Letter stated that Granules’ ANDA for the generic version of Adzenys contains a Paragraph IV certification alleging that these patents are not valid, not enforceable, and/or will not be infringed by the commercial manufacture, use or sale of the generic version of Adzenys. We timely filed a patent infringement lawsuit on December 11, 2024, against Granules to trigger a stay precluding the FDA from approving Granules’ ANDA for a generic version of Adzenys for up to 30 months or entry of judgment holding the patents invalid, unenforceable, or not infringed, whichever occurs first. On January 7, 2025, Granules submitted an answer to the complaint. On June 27, 2025, the Court entered a Stipulation And Order Regarding Infringement finding that the submission of Granules’ ANDA infringed multiple claims in each of our asserted patents. On October 28, 2025, the case was reassigned to visiting judge, Judge Jennifer Choe-Groves of the United States Court of International Trade. The case is ongoing. The trial date has been moved to January 12, 2027. We plan to continue vigorously enforcing our intellectual property rights related to Adzenys.\n\n \n\n32\n\n[Table of Contents](#toc)\n\n \n\n**Results of Operations**\n\n \n\nThe results of operations for the three and nine months ended March 31, 2026, compared to the three and nine months ended March 31, 2025, is as follows:\n\n \n\n \n \n\n**Three Months Ended**\n\n \n \n\n**Nine Months Ended**\n\n \n\n \n \n\n**March 31,**\n\n \n \n\n**March 31,**\n\n \n\n \n \n\n**2026**\n\n \n \n\n**2025**\n\n \n \n\n**Change**\n\n \n \n\n**2026**\n\n \n \n\n**2025**\n\n \n \n\n**Change**\n\n \n\n \n \n\n**(in thousands)**\n\n \n\nNet revenue\n\n \n$\n12,411\n \n \n$\n18,452\n \n \n$\n(6,041\n)\n \n$\n41,464\n \n \n$\n51,247\n \n \n$\n(9,783\n)\n\nCost of goods sold\n\n \n \n4,812\n \n \n \n5,646\n \n \n \n(834\n)\n \n \n15,055\n \n \n \n15,670\n \n \n \n(615\n)\n\nGross profit\n\n \n \n7,599\n \n \n \n12,806\n \n \n \n(5,207\n)\n \n \n26,409\n \n \n \n35,577\n \n \n \n(9,168\n)\n\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n\nOperating expenses:\n\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n\nSelling and marketing\n\n \n \n5,929\n \n \n \n5,194\n \n \n \n735\n \n \n \n17,249\n \n \n \n16,125\n \n \n \n1,124\n \n\nGeneral and administrative\n\n \n \n4,973\n \n \n \n4,109\n \n \n \n864\n \n \n \n14,967\n \n \n \n13,683\n \n \n \n1,284\n \n\nResearch and development\n\n \n \n—\n \n \n \n162\n \n \n \n(162\n)\n \n \n—\n \n \n \n1,110\n \n \n \n(1,110\n)\n\nAmortization of intangible assets\n\n \n \n761\n \n \n \n920\n \n \n \n(159\n)\n \n \n1,731\n \n \n \n2,762\n \n \n \n(1,031\n)\n\nRestructuring costs\n\n \n \n—\n \n \n \n—\n \n \n \n—\n \n \n \n—\n \n \n \n2,101\n \n \n \n(2,101\n)\n\nTotal operating expenses\n\n \n \n11,663\n \n \n \n10,385\n \n \n \n1,278\n \n \n \n33,947\n \n \n \n35,781\n \n \n \n(1,834\n)\n\n**(Loss) income from operations**\n\n \n \n**(4,064**\n**)**\n \n \n**2,421**\n** **\n \n \n**(6,485**\n**)**\n \n \n**(7,538**\n**)**\n \n \n**(204**\n)\n \n \n**(7,334**\n**)**\n\nOther income, net\n\n \n \n149\n \n \n \n36\n \n \n \n113\n \n \n \n540\n \n \n \n718\n \n \n \n(178\n)\n\nInterest expense\n\n \n \n(436\n)\n \n \n(900\n)\n \n \n464\n \n \n \n(1,512\n)\n \n \n(2,973\n)\n \n \n1,461\n \n\nDerivative warrant liabilities (loss) gain\n\n \n \n(1,257\n)\n \n \n2,261\n \n \n \n(3,518\n)\n \n \n(5,717\n)\n \n \n8,157\n \n \n \n(13,874\n)\n\n**(Loss) income from continuing operations before income tax expense**\n\n \n \n**(5,608**\n)\n \n \n**3,818**\n \n \n \n**(9,426**\n)\n \n \n**(14,227**\n**)**\n \n \n**5,698**\n** **\n \n \n**(19,925**\n)\n\nIncome tax (expense) benefit\n\n \n \n(10\n)\n \n \n122\n \n \n \n(132\n)\n \n \n(10\n)\n \n \n—\n \n \n \n(10\n)\n\n**Net (loss) income from continuing operations**\n\n \n \n**(5,618**\n)\n \n \n**3,940**\n \n \n \n**(9,558**\n)\n \n \n**(14,237**\n**)**\n \n \n**5,698**\n** **\n \n \n**(19,935**\n)\n\nNet income from discontinued operations, net of tax\n\n \n \n—\n \n \n \n54\n \n \n \n(54\n)\n \n \n—\n \n \n \n558\n \n \n \n(558\n)\n\n**Net (loss) income**\n\n \n$\n**(5,618**\n)\n \n$\n**3,994**\n \n \n$\n**(9,612**\n)\n \n$\n**(14,237**\n)\n \n$\n**6,256**\n** **\n \n$\n**(20,493**\n)\n\n \n\n**Net Revenue by Product Portfolio**\n\n \n\nNet revenue disaggregated by product portfolios for the three and nine months ended March 31, 2026, compared to the three and nine months ended March 31, 2025, is as follows:\n\n \n\n \n \n\n**Three Months Ended**\n\n \n \n\n**Nine Months Ended**\n\n \n\n \n \n\n**March 31,**\n\n \n \n\n**March 31,**\n\n \n\n \n \n\n**2026**\n\n \n \n\n**2025**\n\n \n \n\n**Change**\n\n \n \n\n**2026**\n\n \n \n\n**2025**\n\n \n \n\n**Change**\n\n \n\n \n \n\n**(in thousands)**\n\n \n\nEXXUA\n\n \n$\n2,397\n \n \n$\n—\n \n \n$\n2,397\n \n \n$\n2,638\n \n \n$\n—\n \n \n$\n2,638\n \n\nADHD Portfolio\n\n \n \n9,093\n \n \n \n15,389\n \n \n \n(6,296\n)\n \n \n35,465\n \n \n \n44,469\n \n \n \n(9,004\n)\n\nPediatric Portfolio\n\n \n \n921\n \n \n \n3,059\n \n \n \n(2,138\n)\n \n \n3,325\n \n \n \n6,752\n \n \n \n(3,427\n)\n\nOther\n\n \n \n—\n \n \n \n4\n \n \n \n(4\n)\n \n \n36\n \n \n \n26\n \n \n \n10\n \n\nTotal net revenue\n\n \n$\n12,411\n \n \n$\n18,452\n \n \n$\n(6,041\n)\n \n$\n41,464\n \n \n$\n51,247\n \n \n$\n(9,783\n)\n\n \n\nDuring the three months ended March 31, 2026, net revenue decreased by $6.0 million, or 33%, compared to the same period ended March 31, 2025, primarily due to a broader deemphasis in marketing towards the ADHD Portfolio as our marketing efforts have shifted towards EXXUA, which is now the centerpiece of our commercial efforts as well as a decrease in ADHD Portfolio net revenue attributed to the launch of a generic version of one of our ADHD products late in the second quarter of fiscal 2026. The Pediatric Portfolio was negatively impacted by payer mix resulting in higher rebates and an increase in returns. These decreases were partially offset by a $2.4 million increase in net revenue related to the successful new product launch of EXXUA in the second quarter of fiscal 2026. \n\n \n\n33\n\n[Table of Contents](#toc)\n\n \n\nDuring the nine months ended March 31, 2026, net revenue decreased by $9.8 million, or 19%, compared to the same period ended March 31, 2025, primarily due to a broader deemphasis in marketing towards the ADHD Portfolio as our marketing efforts have shifted towards EXXUA, which is now the centerpiece of our commercial efforts, and a decrease in ADHD Portfolio net revenue attributed to the launch of a generic version of one of our ADHD products late in the second quarter of fiscal 2026. The decrease in the Pediatric Portfolio was primarily due to returns experienced during the quarter. These decreases were partially offset by a $2.6 million increase in net revenue related to the successful new product launch of EXXUA in the second quarter of fiscal 2026 and $3.3 million of net revenue recorded in the first quarter of fiscal 2025 related to a decrease in estimated variable consideration as a result of successful negotiations with a vendor.\n\n \n\n**Gross Profit**\n\n \n\nGross profit and gross profit percentage for the three and nine months ended March 31, 2026, compared to the three and nine months ended March 31, 2025, is as follows:\n\n \n\n \n \n\n**Three Months Ended**\n\n \n \n\n**Nine Months Ended**\n\n \n\n \n \n\n**March 31,**\n\n \n \n\n**March 31,**\n\n \n\n \n \n\n**2026**\n\n \n \n\n**2025**\n\n \n \n\n**Change**\n\n \n \n\n**2026**\n\n \n \n\n**2025**\n\n \n \n\n**Change**\n\n \n\n \n \n\n**(in thousands, except gross profit percentage)**\n\n \n\nGross profit\n\n \n$\n7,599\n \n \n$\n12,806\n \n \n$\n(5,207\n)\n \n$\n26,409\n \n \n$\n35,577\n \n \n$\n(9,168\n)\n\nGross profit percentage\n\n \n \n61\n%\n \n \n69\n%\n \n \n(8\n)%\n \n \n64\n%\n \n \n69\n%\n \n \n(5\n)%\n\n \n\nDuring the three months ended March 31, 2026, gross profit decreased by $5.2 million, or 41%, compared to the same period ended March 31, 2025. Gross profit percentage was 61% for the three months ended March 31, 2026, compared to 69% for the same period ended March 31, 2025. The decrease in gross profit percentage is primarily related to a $6.0 million decrease in net revenue driven by a broader deemphasis in marketing towards the ADHD Portfolio as our marketing efforts have shifted towards EXXUA and a $0.7 million inventory write-down recorded to cost of goods sold primarily resulting from a shift from our Adzenys branded products to the Adzenys generic products.\n\n \n\nDuring the nine months ended March 31, 2026, gross profit decreased by $9.2 million, or 26%, compared to the same period ended March 31, 2025. Gross profit percentage was 64% for the nine months ended March 31, 2026, compared to 69% for the same period ended March 31, 2025. This decrease in gross profit percentage is primarily related to a decrease in net revenue driven by a broader deemphasis in marketing towards the ADHD Portfolio as our marketing efforts have shifted towards EXXUA, a $3.3 million increase in net revenue in the first quarter of fiscal 2025 related to a decrease in estimated variable consideration as a result of successful negotiations with a vendor and a $1.8 million inventory write-down recorded to cost of goods sold primarily resulting from a shift from our Adzenys branded products to the Adzenys generic products. These decreases were partially offset by a $2.6 million increase in net revenue related to the successful new product launch of EXXUA in the second quarter of fiscal 2026. \n\n \n\n**Selling and Marketing**\n\n \n\nDuring the three and nine months ended March 31, 2026, selling and marketing expense increased by $0.7 million, or 14% and $1.1 million, or 7% compared to the same periods ended March 31, 2025, primarily driven by increases in labor, service costs and EXXUA launch costs.\n\n \n\n**General and Administrative**\n\n \n\nDuring the three and nine months ended March 31, 2026, general and administrative expense increased by $0.9 million, or 21% and $1.3 million, or 9% compared to the same periods ended March 31, 2025, primarily driven by increases in labor, service costs and EXXUA launch costs, partially offset by improved operational efficiencies such as reduced facilities expense.\n\n \n\n**Research and Development**\n\n \n\nDuring the three and nine months ended March 31, 2026, there was no research and development expense compared to $0.2 million and $1.1 million for the same periods ended March 31, 2025, respectively, primarily driven by our previously announced suspension of our development programs to focus on our commercial operations resulting in a decrease in research and development spending.\n\n \n\n34\n\n[Table of Contents](#toc)\n\n \n\n**Amortization of Intangible Assets**\n\n \n\nDuring the three and nine months ended March 31, 2026, amortization expense of intangible assets, excluding amounts included in cost of goods sold, decreased by $0.2 million, or 17% and $1.0 million, or 37% compared to the same periods ended March 31, 2025, respectively, primarily due to impairments of certain intangible assets recorded in fiscal 2025, partially offset by increased amortization expense from new intangible assets placed into service upon the launch of EXXUA in the second quarter of fiscal 2026.\n\n \n\n**Restructuring Costs**\n\n \n\nDuring the three and nine months ended March 31, 2026, we incurred zero restructuring costs compared to zero and $2.1 million during the same periods ended March 31, 2025, respectively. Restructuring costs during the first half of fiscal 2025 related to our previously announced operational realignment and related costs, which was completed during fiscal 2025.\n\n \n\n**Other Income, Net**\n\n \n\nDuring the three and nine months ended March 31, 2026, other income, net was relatively consistent compared to the same periods ended March 31, 2025.\n\n \n\n**Interest Expense**\n\n \n\nDuring the three and nine months ended March 31, 2026, interest expense decreased by $0.5 million, or 52% and $1.5 million, or 49% compared to the same periods ended March 31, 2025, respectively, primarily due to the paydown of our fixed payment arrangements.\n\n \n\n**Derivative Warrant Liabilities (Loss) Gain**\n\n \n\nThe fair value of derivative warrant liabilities is calculated using either the Black-Scholes option pricing model or the Monte Carlo simulation model and is revalued at each reporting period, and changes are reflected through income or expense. For the three and nine months ended March 31, 2026, we recognized a loss of $1.3 million and $5.7 million, respectively, from the fair value adjustment primarily driven by an increase in our stock price during the three and nine months ended March 31, 2026, partially offset by gains from the exercise of liability classified warrants. For the three and nine months ended March 31, 2025, we recognized a gain of $2.3 million and $8.2 million, respectively, from the fair value adjustment primarily driven by a decrease in our stock price during the three and nine months ended March 31, 2025.\n\n \n\n***Income Tax (Expense) Benefit***\n\n \n\nFor both the three and nine months ended March 31, 2026, there was less than $0.1 million of income tax expense from continuing operations, which was an effective tax rate of negative 0.2% and negative 0.1%. This was primarily driven by operating losses and favorable deductions from tax law changes coupled with existing valuation allowances and adjustments from our income tax return filings\n\n \n\nFor the three and nine months ended March 31, 2025, we recorded an income tax benefit of $0.1 million from continuing operations, which represented an effective tax rate of negative 3.2% and an income tax expense of zero, which represented an effective tax rate of zero. These effective tax rates were primarily driven by the limitations on losses as a result of Section 382 of the Internal Revenue Code changes in ownership coupled with existing valuation allowances, the divestiture of our Consumer Health business that occurred during the first quarter of fiscal 2025 and changes to our fiscal 2025 projections, which resulted in an income tax benefit for the three months ended March 31, 2025, that reduced income tax expense for the nine months ended March 31, 2025, to zero.\n\n \n\n***Net Income from Discontinued Operations, Net of Tax***\n\n \n\nNet income from discontinued operations, net of tax is related to the wind down and divestiture of our Consumer Health business that was completed in the first quarter of fiscal 2025. See *Part I, Item 1, Note 20 – Discontinued Operations*of this Form 10-Q for further detail.\n\n \n\n35\n\n[Table of Contents](#toc)\n\n \n\n**Liquidity and Capital Resources**\n\n \n\n**Sources of Liquidity**\n\n \n\nWe have obligations related to our loan agreements, milestone payments for licensed products, and manufacturing purchase commitments. We finance our operations through a combination of sales of our common stock and warrants, borrowings under our revolving credit facility and from cash generated from operations.\n\n \n\n**Shelf Registrations**\n\n \n\nOn September 26, 2024, we filed the 2024 Shelf registration statement on Form S-3, which was declared effective by the SEC on October 15, 2024. The Shelf Registration statement covers the offering, issuance and sale by us of up to an aggregate of $100.0 million of our common stock, preferred stock, debt securities, warrants, rights and units. Through the filing date of this Annual Report, $100.0 million remains available under the 2024 Shelf. This availability is subject to the SEC’s “baby shelf” limitation as set forth in SEC Instruction I.B.6 limitation to the Form S-3.\n\n \n\n**Equity Financing**\n\n \n\nWe have engaged in several different types of equity financings throughout our history. Most recently in June 2025, we raised gross proceeds of $16.6 million from the issuance of (i) 2,806,688 shares of our common stock, at a public offering price of $1.50 and 8,233,332 prefunded warrants at a public offering price of $1.4999 to purchase 8,233,332 shares of our common stock at an exercise price of $0.0001 per share. We received $14.8 million in proceeds net of underwriting commissions and offering expenses and intend to use the net proceeds from the offering for working capital, general corporate purposes and to enable us to exclusively commercialize EXXUA.\n\n \n\nIn June 2024, the June 2023 Tranche B Warrants to purchase 2,173,912 shares of our common stock at an exercise price of $1.59 were exercised, generating proceeds of $3.5 million. The June Tranche B Warrants were converted into 367,478 shares of our common stock and 1,806,434 prefunded warrants to purchase shares of our common stock with an exercise price of $0.0001 per share. We used a portion of these proceeds as part of a $15.0 million term loan repayment made in June of 2024. For further information on our equity financings and related warrants outstanding, please refer to *Note 14 - Stockholders*’*Equity* and *Note 16 - Warrants* in Part I, Item 1 of this Form 10-Q.\n\n \n\n**Eclipse Agreement**\n\n \n\nUnder our Eclipse Agreement, we have two loan agreements, the Eclipse Term Loan and the Eclipse Revolving Loan. The Eclipse Term Loan consists of an outstanding principal amount of $13.0 million on the closing date of the Eclipse Amendment No. 6, at an interest rate of the SOFR plus 7.0%, with a four-year term and a straight-line loan amortization period of seven years, which would provide for a loan balance at the end of the four-year term of $5.6 million to be repaid on the June 12, 2029, maturity date, as amended. In June 2024, we used the initial proceeds from the Eclipse Term Loan and a portion of the proceeds from the warrant exercises described above to repay in full a $15.0 million term loan. The Eclipse Revolving Loan has a potential maximum borrowing base of $14.5 million at an interest rate of the SOFR plus 4.5%, which was temporarily increased pursuant to the $1.5 million Eclipse Incremental Advance, with repayment and permanent reduction of the Eclipse Incremental Advance commencing on August 1, 2025, and continuing on the first day of each calendar month thereafter, in an amount equal to $125,000 per month, until the Eclipse Incremental Advance has been reduced to zero. In addition, we are required to pay an unused line fee of 0.5% of the average unused portion of the maximum Eclipse Revolving Loan amount during the immediately preceding month. The ability to make borrowings and obtain advances of the Eclipse Revolving Loan remains subject to a borrowing base and reserve, and availability blockage requirements and the maturity date, as amended, is June 12, 2029. Please refer to *Note 10 - Revolving Credit Facility* and *Note 11 - Debt* in Part I, Item 1 of this Form 10-Q for further information.\n\n \n\n**Cash Flows**\n\n \n\nThe following table shows cash flows for the nine months ended March 31, 2026, and 2025:\n\n \n\n \n \n\n**Nine Months Ended March 31,**\n\n** **\n\n \n \n\n**2026**\n\n \n \n\n**2025**\n\n \n \n\n**Change**\n\n \n\n \n \n\n**(in thousands)**\n\n \n\nNet cash used in operating activities\n\n \n$\n(1,125\n)\n \n$\n(4,740\n)\n \n$\n3,615\n \n\nNet cash (used in) provided by investing activities\n\n \n$\n(17\n)\n \n$\n457\n \n \n$\n(474\n)\n\nNet cash (used in) provided by financing activities\n\n \n$\n(3,095\n)\n \n$\n2,450\n \n \n$\n(5,545\n)\n\n \n\n36\n\n[Table of Contents](#toc)\n\n \n\n**Net Cash Used in Operating Activities**\n\n \n\nDuring the nine months ended March 31, 2026, net cash used in operating activities totaled $1.1 million, which was primarily the result of an increase in accrued liabilities and accounts payable, a decrease in prepaid expenses and other current assets as well as negative cash earnings (net loss partially offset by non-cash items primarily from depreciation and amortization, stock-based compensation expense, derivative warrant liabilities adjustment, inventory write-down and other certain non-cash adjustments), partially offset by a decrease in accounts receivable, inventories and other operating assets and liabilities, net.\n\n \n\nDuring the nine months ended March 31, 2025, net used in operating activities totaled $4.7 million, which was primarily the result of an increase in accounts receivable, net and prepaid expenses and other current assets as well as a decrease in accounts payable and accrued liabilities, partially offset by positive cash earnings (net income of $6.3 million partially offset primarily by non-cash depreciation, amortization and accretion, stock compensation expense and derivative warrant liabilities adjustment).\n\n \n\n**Net Cash (Used in) Provided by Investing Activities**\n\n \n\nNet cash used in investing activities was nominal during the nine months ended March 31, 2026. Net cash provided by investing activities for the nine months ended March 31, 2025, was driven by cash received from the sale of fixed assets, partially offset by cash payments for fixed asset purchases.\n\n \n\n**Net Cash (Used in) Provided by Financing Activities**\n\n \n\nNet cash used in financing activities of $3.1 million during the nine months ended March 31, 2026, was primarily due to $3.1 million of payments for fixed payment arrangements and $1.4 million of payments made against the principal balance of our Eclipse Term Loan, partially offset by $1.3 million of net proceeds received from our Eclipse Revolving Loan. \n\n \n\nNet cash provided by financing activities of $2.5 million during the nine months ended March 31, 2025, was primarily due to $7.6 million of net proceeds received from our Eclipse Revolving Loan, partially offset by $3.8 million of payments made to fixed payment arrangements and $1.4 million of payments made on borrowings. \n\n \n\n**Contractual Obligations, Commitments and Contingencies**\n\n \n\nAs a result of our acquisitions, exclusive commercialization agreement, and licensing agreements, we are contractually and contingently obliged to pay, when due, various fixed and contingent milestone payments. See *Note 13 *- *Commitments and Contingencies* in Part I, Item 1 of this Form 10-Q for further information.\n\n \n\nIn May 2022, we entered into an agreement with Tris to terminate the License, Development, Manufacturing and Supply Agreement dated November 2, 2018, related to Tuzistra (the “Tuzistra License Agreement”). Pursuant to such termination we accrued a settlement liability, which was paid in full during the first quarter of fiscal 2026.\n\n \n\nUpon closing of the acquisition of a line of prescription pediatric products from Cerecor, Inc. in October 2019, we assumed payment obligations that required us to make fixed and product milestone payments. As of March 31, 2026, we had no remaining fixed payment arrangement accruals recorded in our unaudited consolidated balance sheet.\n\n \n\nIn connection with our suspension of active development of AR101 (enzastaurin) (“AR101”), we engaged in negotiations with EnzCo, LLC (“EnzCo”) and Rumpus VEDS LLC, (“Rumpus VEDS”), Rumpus Therapeutics LLC, (“Rumpus Therapeutics”) and Rumpus Vascular LLC, (“Rumpus Vascular” and, together with Rumpus VEDS and Rumpus Therapeutics, “Rumpus”) for the repurchase of AR101. In the first quarter of fiscal 2026, we reached terms with Rumpus and EnzCo whereby for mutual consideration and releases, we transferred all of ours and Rumpus’ rights, title and interest in AR101 to EnzCo, which extinguished and terminated all of our obligations and Rumpus’ obligations under the April 21, 2021, asset purchase agreement by and between us and Rumpus (the “Rumpus Asset Purchase Agreement”). There is no other relationship between us, EnzCo or Rumpus other than as contracting parties to terminate the Rumpus Asset Purchase Agreement, and there are no penalties or remaining obligations for us for terminating the Rumpus Asset Purchase Agreement.\n\n \n\n37\n\n[Table of Contents](#toc)\n\n \n\n**Critical Accounting Estimates**\n\n \n\nThe discussion and analysis of our financial condition and results of operations are based upon our financial statements, which have been prepared in accordance with U.S. GAAP. The preparation of these financial statements requires us to make estimates and judgments that affect the amounts of assets, liabilities, revenue and expenses, and related disclosure of contingent assets and liabilities. On an on-going basis, we evaluate our estimates based on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. For a detailed discussion about our critical accounting estimates, refer to our [2025 Form 10-K](http://www.sec.gov/ix?doc=/Archives/edgar/data/1385818/000143774925029723/aytu20250630c_10k.htm).\n\n \n\n**Off-Balance Sheet Arrangements**\n\n \n\nWe have not entered into any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenue or expenses, results of operations, liquidity, capital expenditures or capital resources and would be considered material to investors.\n\n \n\n**ITEM** **3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK**\n\n \n\nWe are a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and are not required to provide information under this item.\n\n \n\n**ITEM** **4. CONTROLS AND PROCEDURES**\n\n \n\n**Evaluation of Disclosure Controls and Procedures**\n\n \n\nAs required by Rules 13a-15(e) and 15d-15(e) under the Exchange Act, our management, with the participation of our Chief Executive Officer and Chief Financial Officer, carried out an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures as of the end of the period covered by this Form 10-Q. Based on this evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that our disclosure controls and procedures were effective as of March 31, 2026, at reasonable assurance levels, in ensuring that information required to be disclosed by us in reports that we file or submit under the Exchange Act (i) is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and (ii) is accumulated and communicated to our management, including our principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure. Accordingly, we believe that the financial statements presented in this Form 10-Q present fairly, in all material respects, our financial position, results of operations and cash flows for the periods presented herein.\n\n \n\n**Inherent Limitations on Effectiveness of Internal Controls over Financial Reporting**\n\n \n\nOur management team, including our Chief Executive Officer and Chief Financial Officer, does not expect that our disclosure controls and procedures will prevent all error and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. The design of any system of controls is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within our Company have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdown can occur because of simple errors or mistakes. In particular, many of our current processes rely upon manual reviews and processes to ensure that neither human error nor system weakness has resulted in erroneous reporting of financial data.\n\n \n\n**Changes in Internal Control over Financial Reporting**\n\n \n\nThere have been no changes to our internal control over financial reporting (as defined in Rule 13a-15(f) under the Exchange Act) that occurred during the quarter ended March 31, 2026, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.\n\n \n\n38\n\n[Table of Contents](#toc)\n\n \n\n**PART** **II. OTHER INFORMATION**"}